Cipher Pharmaceuticals Inc(CPH-T)
TSX

Today's Change
Real-Time Last Update
Day Low17.35
Day High18.46
Open:18.12
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newswire.ca
Cipher Pharmaceuticals Schedules Q2 2026 Earnings Release and Conference Call
Newswire.ca
Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®
Newswire.ca
Cipher Pharmaceuticals Announces Results of Annual General Meeting of Shareholders
Stock Target Advisor
Canadian Analyst Updates: May 12th, 2026
Canadian Analyst Updates: May 12th, 2026
Newswire.ca
Cipher Pharmaceuticals Reports First Quarter Results
Newsfile
Upcoming Meeting Dates - May 4, 2026
Newswire.ca
Cipher Pharmaceuticals Announces Normal Course Issuer Bid
Newswire.ca
Cipher Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call
Newsfile
Upcoming Meeting Dates - April 20, 2026
Newswire.ca
Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings
Newswire.ca
Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call
The Globe and Mail
Top Canadian stocks that combine quant strength and bullish charts
For Number Cruncher column in Globe Investor/ROB only.
Newswire.ca
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad)
The Globe and Mail
Why this money manager is buying Blue Ant Media and selling Constellation Software
Jesse Gamble, senior vice-president and portfolio manager at Toronto-based Donville Kent Asset Management Inc. Illustration by Joel Kimmel
The Globe and Mail
Small caps to watch: Exchange Income and NFI Group among stocks that could see big earnings-related moves today
After Marc Cohodes’ revealed his Exchange Income short on Wednesday, the stock fell nearly 10 per cent in early trading before closing at $31.10, a 4.7-per-cent decline from Tuesday’s close.
Newswire.ca
Cipher Pharmaceuticals Reports Third Quarter 2025 Results
Newswire.ca
Cipher Pharmaceuticals Schedules Q3 2025 Earnings Release and Conference Call
Baystreet
Stocks in play: Cipher Pharmaceuticals Inc.
Newswire.ca
Cipher Pharmaceuticals Receives Successful Arbitration Award

Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.